A $452 million adverse jury verdict in the medical technology sector is often viewed as an existential threat. EOFlow faced severe legal, financial, and market pressure after the U.S. District Court for the District of Massachusetts issued a damages verdict in a high-profile trade secret dispute with Insulet. The challenge was to determine whether the verdict represented a terminal risk or a mispriced opportunity.
Dr. Shim reviewed thousands of pages of evidence and key principles of federal trade secret law. His analysis identified two decisive vulnerabilities: fundamental defects in Insulet’s core theory and a clear abuse of discretion by the trial court. Based on this assessment, he presented investors with a structured case that EOFlow had both the factual and legal foundation to overturn the verdict on appeal.
On January 24, 2025, just weeks after the verdict, investors backed Dr. Shim’s analysis and provided critical capital to EOFlow through IPV, the biotech IP management company he leads. His thesis was ultimately validated on May 28, 2026, when the U.S. Court of Appeals for the Federal Circuit vacated the $452 million verdict.
This case demonstrates how rigorous legal analysis, investment conviction, and strategic IP judgment can transform a seemingly catastrophic litigation outcome into a decisive legal and financial turnaround. Related Coverage Reuters “Insulet wins $452M US verdict against EOFlow in insulin pump secrets case” December 6, 2024 https://www.reuters.com/business/healthcare-pharmaceuticals/insulet-wins-452-mln-us-verdict-against-eoflow-insulin-pump-secrets-case-2024-12-05/ Cooley “EOFlow wins Federal Circuit Appeal overturning $452 Million jury verdict” May 28, 2026 https://www.cooley.com/news/coverage/2026/2026-05-28-eoflow-wins-federal-circuit-appeal-overturning-$452-million-jury-verdict
Next projects.
(2019-26©)
